14
Adrian Towse Director of the Office of Health Economics Visiting Professor London School of Economics HTAi Tokyo May 2016 Operationalising Value-based Pricing: Do we know what we Value and What we are giving up to get it?

Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

Embed Size (px)

Citation preview

Page 1: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

Adrian TowseDirector of the Office of Health EconomicsVisiting Professor London School of Economics

HTAi Tokyo May 2016

Operationalising Value-based Pricing: Do we know what we Value and What we are giving up to get it?

Page 2: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Background

In UK, decisions to approve/reject new health care technologies taken by Health Technology Assessment (HTA) agencies:

• National Institute for Health and Care Excellence (NICE) in England

• All Wales Medicines Strategy Group (AWMSG) in Wales

• Scottish Medicines Consortium (SMC) in Scotland

Page 3: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

England – NICE Threshold

Question asked by Claxton et al. (2015):• On average, across PCTs in England, how

much does it cost to produce one QALY?• Argued to represent opportunity cost of HTA

recommendations• E.g. if NICE recommends new technology which

requires more NHS funds per QALY gained than this average overall decrease in QALYs produced by health service (displacement effect)

“Best estimate” = £12,936 per QALY gained

Page 4: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

England: Data limitations

Key issue = substantial data limitations1. Absence of quality of life (QoL) data authors use mortality

data and make series of transformations to adjust for QoL2. Incomplete mortality data – good quality data available for

only 4/23 Programme Budget Categories; poorer quality data available for additional 7

3. Absence of time-series data authors forced to use estimated differences across PCTs as proxy for differences within PCTs over time

Key consequence of data limitations = strong assumptions high degree of uncertainty

Page 5: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

England: Key assumptionsKey assumptions:

1. Duration of effect of expenditure on mortality2. Future mortality risk of patients saved due to increased expenditure3. Future quality of life of patients saved due to increased expenditure

Best estimate of £12,936 is product of particular combination of “conservative” and “optimistic” options for these assumptionsDifferent combinations give very different answersAdditional key assumption not tested: PCTs are as good at achieving QoL gains as at achieving LYGs (DALY disease burden used to pro-rata QoL gains based on LYGs)DH is commissioning the Claxton team to collect new data and test assumptions 1-3OHE has a report of possible future research option (see Karlsberg Shaffer et al., 2016b)

Page 6: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

England: Combinations of three key assumptions

In my view the £30,270 estimate is the most plausible, rather than the £12,936

Page 7: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Scotland: OHE Study DataTwo sources of data for identifying ‘marginal’ services:

1. NHS Budget Scrutiny (2012/13)• Performed by Health and Sport Committee of

Scottish Parliament• Data available for all 14 NHS Boards

2. Semi-structured interviews with Directors of Finance of 12/14 Boards (89% of Scottish population)

Page 8: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Scotland: Data (2)

Relevant budget scrutiny questions:• 4(b): “Please identify the three main

areas in which … savings will be made … in 2012-13”

• 5(a): “Please give three examples of service developments that you have been able to fund in 2012-13”

• 5(b): “Please give three examples of service developments that you would consider priorities, but have been unable to fund in 2012-13”

Threshold upper bound

Threshold lower bound

Threshold upper bound

Page 9: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Scotland: Results

Page 10: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Scotland: Implications• Huge variation in £/QALY estimates – both within and between services• If take median estimate across services, threshold = £1,516–1,017,844

per QALY Not possible to obtain reliable estimate of threshold in Scotland• Cost per QALY evidence never used to justify marginal spending decisions• Decisions driven by range of other factors, e.g.:

• Scottish Government initiatives• Patient convenience• Waiting time targets• Benchmarking against other NHS Boards

• Explicit disinvestment occurs very rarely• Savings generally sought from efficiency improvements

Page 11: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Wales: Methods

Semi-structured interviews with Medical and/or Finance Directors of all 7 Local Health Boards (LHBs) in NHS WalesKey interview sections:

1. Procedures, policies & guidelines for prioritisation at LHB

2. How in practice LHBs found funds to comply with NICE TAs issued in study period (Oct 2010- March 2013)

3. How LHBs accommodated other financial “shocks”

Page 12: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

Wales: Discussion/conclusions

Implicit in displacement assumption is that:• LHB budgets are fixed and fully deployed• Providers are not x-inefficient

Evidence in this paper that opportunity cost is not wholly felt in terms of displacement of other NHS servicesOpportunity cost falls at least in part:

• Outside the NHS (other areas of public spending)• By increased efforts to improve efficiency

Page 13: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

HTAi Tokyo May 2016

ReferencesBarnsley, P., Towse, A., Karlsberg Schaffer, S. and Sussex, J (2013). Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. OHE Occasional Paper at: https://www.ohe.org/publications/critique-che-research-paper-81-methods-estimation-nice-cost-effectiveness-threshold#sthash.xFhhxHHK.dpufClaxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. (2015). Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess;19 (14) Karlsberg Schaffer, S., Sussex, J., Devlin, N., & Walker, A. (2015). Local health care expenditure plans and their opportunity costs. Health Policy, 119(9), 1237-1244Karlsberg Schaffer, S., Sussex, J., Hughes, D., & Devlin, N. (2016a). Opportunity costs and local health service spending decisions: a qualitative study from Wales. BMC Health Services Research, 16(1), 1.Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A. (2016b) Shaping Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making. OHE Consulting. Available at: https://www.ohe.org/publications/shaping-research-agenda-estimate-cost-effectiveness-thresholds-decision-making#sthash.OuKI6Wjl.dpuf

Page 14: Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it?

Adrian TowseThe Office of Health Economics

Registered address Southside, 7th Floor, 105 Victoria Street, London SW1E 6QT

Website: www.ohe.org  Blog: http://news.ohe.orgEmail: [email protected]

THANK YOU FOR YOUR ATTENTION